Off-label and unlicensed oncology medicine use in Turkey: A retrospective analysis of computer records of the Turkish Ministry of Health

Journal of Pharmaceutical Health Services Research

Volumn 2, Issue 1, 2011, Pages 53-57

  Koçkaya, Güvenç ^a   Polat, Mine ^a   Vural, Ismail Mert ^a   Akbulat, Akif ^a   Dedeoglu, Burcak Deniz ^a   Akar, Halil ^a   Kerman, Saim ^a  

^a MINISTRY OF HEALTH   (Turkey)

Author keywords

Off label; Oncology; Unlicensed

Indexed keywords

ARTICLE; AWARENESS; DRUG COST; DRUG INDICATION; ELECTRONIC MEDICAL RECORD; OFF LABEL DRUG USE; PRIORITY JOURNAL; REIMBURSEMENT; RETROSPECTIVE STUDY; SOCIAL SECURITY; TURKEY (REPUBLIC);

EID: 84860410790     PISSN: 17598885     EISSN: 17598893     Source Type: Journal    
DOI: 10.1111/j.1759-8893.2011.00041.x     Document Type: Article

References (12)

1. Graul AI. Promoting, improving and accelerating the drug development and approval processes. Drug News Perspect 2007; 20: 45-55.
2. Stafford RS. Regulating off-label drug use - rethinking the role of the FDA. N Engl J Med 2008; 358: 1427-1429.
3. Radley DC etal. Off-label prescribing among office-based physicians. Arch Intern Med 2006; 166: 1021-1026.
4. Roberts R etal. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA 2003; 290: 905-911.
5. Levêque D. Off-label use of anticancer drugs. Lancet Oncol 2008; 9: 1102-1107.
6. Conroy S etal. Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children. Ann Oncol 2003; 14: 42-47.
7. Anon. 'Off-Label' indications for oncology drug use and drug compendia: history and current status. J Oncol Pract 2005; 1: 102-105.
8. General Medical Council. Good Practice in Prescribing Medicines (September 2008). General Medical Council [online publication]: London, 2008.
9. Casali PG; Executive Committee of ESMO. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol 2007; 18: 1923-1925.
10. Poole SG, Dooley MJ. Off-label prescribing in oncology. Support Care Cancer 2004; 12: 302-305.
11. Kocs D, Fendrick AM. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience. Am J Manag Care 2003; 9: 393-400; quiz 401-402.
12. Cuzzolin L etal. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf 2006; 5: 703-718.